Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of CTMP1 gene on pulmonary fibrosis

  • Huonggiang Nguyen (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Uijin Juang (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Suhwan Gwon (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Woohyeong Jung (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Quingzhi Huang (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Soohyeon Lee (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Beomwoo Lee (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • So Hee Kwon (College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University) ;
  • Seon‑Hwan Kim (Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University) ;
  • Jongsun Park (Department of Pharmacology, College of Medicine, Chungnam National University)
  • Received : 2024.04.14
  • Accepted : 2024.11.13
  • Published : 2025.05.15
⟨ Previous Next ⟩

Abstract

Protein kinase B (PKB/AKT) is a very important member of the protein kinase family, playing signifcant roles in various crucial processes including insulin-signaling, cell survival, growth, and metabolism. The carboxyl-terminal modulator protein 1 (CTMP1) inhibits PKB, primarily by attenuating its phosphorylation. Idiopathic pulmonary fibrosis (IPF) is an irreversible, chronic, progressive pulmonary disorder; the clinical treatment options are limited. Of the various experimental models, bleomycin-induced lung fibrosis is the most extensively studied. It closely resembles human lung fibrosis. We explored the impact of CTMP1 on bleomycin-induced fibrosis. In vitro experiments involved knockdown of CTMP1 in A549 cells (human alveolar epithelial cells), followed by bleomycin treatment. In vivo, lung fibrosis was induced in mice with ablated CTMP1 via intratracheal bleomycin administration at 2 mg/kg. CTMP1 deletion reduced pulmonary fibrosis and the epithelial-to-mesenchymal transition by inhibiting PKB phosphorylation. These findings suggest that CTMP1 plays a pivotal role in the regulation of lung fibrosis, offering new insights into potential therapeutic approaches for IPF patients.

Keywords

Acknowledgement

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certifcate/nkLw5z

References

  1. Saeed S et al (2023) Idiopathic pulmonary fibrosis in a young adult: a rare presentation and management challenges. Cureus 15:e43010 https://doi.org/10.7759/cureus.43010
  2. Yu QY, Tang XX (2022) Irreversibility of pulmonary fibrosis. Aging Dis 13:73–86 https://doi.org/10.14336/AD.2021.0730
  3. Maher TM et al (2021) Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22:197 https://doi.org/10.1186/s12931-021-01791-z
  4. Fernandez Fabrellas E et al (2018) Prognosis and follow-up of idiopathic pulmonary fibrosis. Med Sci (Basel) 6:51 https://doi.org/10.3390/medsci6020051
  5. Diamantopoulos A et al (2018) The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review. Pharmacoeconomics 36:779–807 https://doi.org/10.1007/s40273-018-0631-8
  6. Lee JH et al (2023) Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study. BMC Pulm Med 23:54 https://doi.org/10.1186/s12890-023-02340-8
  7. Brandt JP, Gerriets V (2023) Bleomycin. In: StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Valerie Gerriets declares no relevant financial relationships with ineligible companies
  8. Azambuja E et al (2005) Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther 18:363–366 https://doi.org/10.1016/j.pupt.2005.01.007
  9. Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120:617–624 https://doi.org/10.1378/chest.120.2.617
  10. O'Sullivan JM et al (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91–96 https://doi.org/10.1093/annonc/mdg020
  11. Peng R et al (2013) Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for 'active' disease. PLoS One 8:e59348 https://doi.org/10.1371/journal.pone.0059348
  12. Fernandez IE, Eickelberg O (2012) The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 9:111–116 https://doi.org/10.1513/pats.201203-023AW
  13. Hogan BL et al (2014) Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell 15:123–138 https://doi.org/10.1016/j.stem.2014.07.012
  14. Salton F, Volpe MC, Confalonieri M (2019) Epithelial(-)mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis. Medicina (Kaunas) 55:83 https://doi.org/10.3390/medicina55040083
  15. Jolly MK et al (2018) Epithelial-mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease. Dev Dyn 247:346–358 https://doi.org/10.1002/dvdy.24541
  16. Acloque H et al (2009) Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119:1438–1449 https://doi.org/10.1172/JCI38019
  17. Maira SM et al (2001) Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294:374–380 https://doi.org/10.1126/science.1062030
  18. Ye Z, Hu Y (2021) TGF-beta1: gentlemanly orchestrator in idiopathic pulmonary fibrosis (review). Int J Mol Med 48:132 https://doi.org/10.3892/ijmm.2021.4965
  19. Wang J et al (2022) Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm Sin B 12:18–32 https://doi.org/10.1016/j.apsb.2021.07.023
  20. Liu X et al (2018) Carboxyl-terminal modulator protein ameliorates pathological cardiac hypertrophy by suppressing the protein kinase B signaling pathway. J Am Heart Assoc 7:e008654 https://doi.org/10.1161/JAHA.118.008654
  21. Chen N et al (2016) Carboxy-terminal modulator protein attenuated extracellular matrix deposit by inhibiting phospho-Akt, TGFbeta1 and alpha-SMA in kidneys of diabetic mice. Biochem Biophys Res Commun 474:753–760 https://doi.org/10.1016/j.bbrc.2016.05.032
  22. Li H et al (2017) Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. Sci Rep 7:46754 https://doi.org/10.1038/srep46754
  23. Geng Y et al (2022) PEAR1 regulates expansion of activated fibroblasts and deposition of extracellular matrix in pulmonary fibrosis. Nat Commun 13:7114 https://doi.org/10.1038/s41467-022-34870-w
  24. Kim YS et al (2019) The anti-fibrotic effects of CG-745, an HDAC inhibitor, in bleomycin and PHMG-induced mouse models. Molecules 24:2792 https://doi.org/10.3390/molecules24152792
  25. Cowley PM, Roberts CR, Baker AJ (2019) Monitoring the health status of mice with bleomycin-induced lung injury by using body condition scoring. Comp Med 69:95–102 https://doi.org/10.30802/AALAS-CM-18-000060
  26. Hubner RH et al (2008) Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44:507–511 https://doi.org/10.2144/000112729
  27. Vo TT et al (2023) AXL is required for hypoxia-mediated hypoxia-inducible factor-1 alpha function in glioblastoma. Toxicol Res 39:669–679 https://doi.org/10.1007/s43188-023-00195-z
  28. Chen KJ et al (2016) Bleomycin (BLM) induces epithelial-tomesenchymal transition in cultured A549 cells via the TGF-beta/Smad signaling pathway. J Cancer 7:1557–1564 https://doi.org/10.7150/jca.15566
  29. Rao LZ et al (2021) Correction: IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages. Cell Death Differ 28:2989 https://doi.org/10.1038/s41418-020-00721-8
  30. Kim SN et al (2010) Dose-response effects of bleomycin on inflammation and pulmonary fibrosis in mice. Toxicol Res 26:217–222 https://doi.org/10.5487/TR.2010.26.3.217
  31. Wolters PJ, Collard HR, Jones KD (2014) Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 9:157–179 https://doi.org/10.1146/annurev-pathol-012513-104706
  32. Smith ML (2022) The histologic diagnosis of usual interstitial pneumonia of idiopathic pulmonary fibrosis. Where we are and where we need to go. Mod Pathol 35(Suppl 1):8–14 https://doi.org/10.1038/s41379-021-00889-5
  33. Selman M, Pardo A (2014) Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med 189:1161–1172 https://doi.org/10.1164/rccm.201312-2221PP
  34. Keshavan S et al (2023) Comparing species-different responses in pulmonary fibrosis research: current understanding of in vitro lung cell models and nanomaterials. Eur J Pharm Sci 183:106387 https://doi.org/10.1016/j.ejps.2023.106387
  35. Moeller A et al (2008) The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40:362–382 https://doi.org/10.1016/j.biocel.2007.08.011
  36. Ju N et al (2022) Prevention of bleomycin-induced pulmonary fibrosis by a RANKL peptide in mice. Sci Rep 12:12474 https://doi.org/10.1038/s41598-022-16843-7
  37. Chang J et al (2021) Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung. Sci Rep 11:16525 https://doi.org/10.1038/s41598-021-96152-7
  38. Manning BD, Toker A (2017) AKT/PKB signaling: navigating the network. Cell 169:381–405 https://doi.org/10.1016/j.cell.2017.04.001
  39. Parcellier A et al (2009) The Carboxy-Terminal Modulator Protein (CTMP) regulates mitochondrial dynamics. PLoS One 4:e5471 https://doi.org/10.1371/journal.pone.0005471
  40. Regev-Rudzki N, Yogev O, Pines O (2008) The mitochondrial targeting sequence tilts the balance between mitochondrial and cytosolic dual localization. J Cell Sci 121:2423–2431 https://doi.org/10.1242/jcs.029207
  41. Holm Nielsen S et al (2019) Serological assessment of activated fibroblasts by alpha-smooth muscle actin (alpha-SMA): a noninvasive biomarker of activated fibroblasts in lung disorders. Transl Oncol 12:368–374 https://doi.org/10.1016/j.tranon.2018.11.004
  42. Tsitoura E et al (2021) Collagen 1a1 expression by airway macrophages increases in fibrotic ILDs and is associated with FVC decline and increased mortality. Front Immunol 12:645548 https://doi.org/10.3389/fimmu.2021.645548
  43. Frangogiannis N (2020) Transforming growth factor-beta in tissue fibrosis. J Exp Med 217:e20190103
  44. Kurowska N et al (2022) Differences in the expression patterns of TGFbeta isoforms and associated genes in astrocytic brain Tumors. Cancers (Basel) 14:1876 https://doi.org/10.3390/cancers14081876
  45. Aschner Y, Downey GP (2016) Transforming growth factor-beta: master regulator of the respiratory system in health and disease. Am J Respir Cell Mol Biol 54:647–655 https://doi.org/10.1165/rcmb.2015-0391TR
  46. Morikawa M, Derynck R, Miyazono K (2016) TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol 8:a021873
  47. Wu L et al (2017) Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-beta1/Smads and PI3K/Akt pathways. Sci Rep 7:9289 https://doi.org/10.1038/s41598-017-09673-5
  48. Runyan CE, Schnaper HW, Poncelet AC (2004) The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta1. J Biol Chem 279:2632–2639 https://doi.org/10.1074/jbc.M310412200
  49. Lee KI et al (2020) Ultrafine silicon dioxide nanoparticles cause lung epithelial cells apoptosis via oxidative stress-activated PI3K/Akt-mediated mitochondria- and endoplasmic reticulum stressdependent signaling pathways. Sci Rep 10:9928 https://doi.org/10.1038/s41598-020-66644-z
  50. Kral JB et al (2016) Sustained PI3K activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and profibrotic pathways. Sci Rep 6:23034 https://doi.org/10.1038/srep23034
  51. Xia H et al (2010) Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 176:2626–2637 https://doi.org/10.2353/ajpath.2010.091117
  52. Molyneaux PL et al (2017) Host-microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 195:1640–1650 https://doi.org/10.1164/rccm.201607-1408OC
  53. Molyneaux PL et al (2014) The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 190:906–913 https://doi.org/10.1164/rccm.201403-0541OC
  54. Han MK et al (2014) Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2:548–556 https://doi.org/10.1016/S2213-2600(14)70069-4
  55. Sheng G et al (2020) Viral infection increases the risk of idiopathic pulmonary fibrosis: a meta-analysis. Chest 157:1175–1187 https://doi.org/10.1016/j.chest.2019.10.032
  56. Meadors M, Floyd J, Perry MC (2006) Pulmonary toxicity of chemotherapy. Semin Oncol 33:98–105 https://doi.org/10.1053/j.seminoncol.2005.11.005
  57. Garcia-Sancho C et al (2011) Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 105:1902-1907 https://doi.org/10.1016/j.rmed.2011.08.022